The loss ratio has held in a fairly narrow 86% to 90% band, so the swings in combined ratio are driven mainly by the expense ratio, which spiked to 15.5% in 2024Q4 before settling near 10.5%. The 2026Q2 print below 97% is the strongest underwriting result in the series, but the immediate reversal to 100.3% in 2026Q3 suggests that quarter-level results may reflect utilization timing rather than a durable improvement in cost structure. Investors should monitor whether the expense ratio stabilizes near current levels while the loss ratio remains below 90%.

Because the reported underwriting margin has oscillated between roughly -3.2% and +3.2%, ROE is effectively a function of small underwriting outcomes amplified by a modest equity base. Investment income is not disclosed in the supplied data, so the contribution of float yield to ROE cannot be separated from underwriting results. The positive 2026Q2 ROE likely reflects a favorable loss-ratio quarter rather than a structural shift in profitability.

A P/B above 1.3 for an insurer with ROE near breakeven implies the market expects sustained returns well above current levels, and the multiple has more than doubled as equity rebuilt. Relative to peers, ALHC's P/B of 1.33 sits below Humana and Molina but above Centene and CVS, which suggests the valuation is not clearly stretched against the group. The premium appears to rest on membership growth and technology-platform optionality rather than demonstrated underwriting profitability.

The improvement in leverage is largely mechanical, as shareholders' equity rose from roughly $100M to $277M while total liabilities grew with membership, so the ratio should be read with caution. Premium-to-surplus cannot be computed directly from the supplied data, but the thin equity cushion relative to a claims base near $1.2B suggests limited absorption capacity for adverse medical cost development. Investors should monitor whether equity growth continues to outpace liability expansion.

The peer set shows ROE clustered in the single digits for Centene, CVS, and Humana, with Elevance the clear return leader at 11.6%, so ALHC's negative quarterly return places it at the bottom of the group. Its P/B of 1.33 is lower than Humana's 2.95 and Molina's 2.61, which implies the market is not awarding ALHC the same franchise premium as larger, profitable payers. This discount is consistent with its unproven margin profile and concentrated California exposure. Investors should monitor whether ALHC can close the return gap while sustaining above-peer growth.